<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561338</url>
  </required_header>
  <id_info>
    <org_study_id>HMM0201</org_study_id>
    <nct_id>NCT02561338</nct_id>
  </id_info>
  <brief_title>A Multi-center 12-week Study of HMS5552 in T2DM</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, 12-week Phase II Study to Evaluate the Safety, Tolerability, Efficacy and Population PK of HMS5552 in Type 2 Diabetic Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hua Medicine Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tigermed Consulting Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hua Medicine Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety, tolerability, efficacy and population PK of HMS5552 in type
      2 diabetic adult subjects,there will be 5 groups ,4 groups will receive HMS5552,while 1 will
      receive placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glucokinase (GK, also called hexokinase IV or D) can phosphosphorylate glucose to
      glucose-6-phosphate (G-6-P) in pancreatic β-cells and liver cells, which represents the first
      step of glucose metabolism. GK also acts as a glucose sensor and exerts a key role in
      maintaining glucose homeostasis. HMS5552 is a 4th-generation GK agonist or activator (GKA),
      which was originally licensed from Roche and subsequently developed by Hua Medicine. HMS5552
      has been shown to activate GK in pancreatic beta cells, liver and intestinal epithelial
      cells. It regulates systemic blood glucose through a variety of mechanisms including directly
      enhancing insulin release (pancreas), inhibiting production of endogenous glucose (liver) and
      by indirectly promoting GLP-1 release (enteroendocrine L-cells).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>After 12-week Treatment, the Change From Baseline in HbA1c</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Assess the percentage of Hemoglobin A1c (HbA1c) changes at week 12. In the group HMS5552 dose3, a subject without follow-up data for HbA1c available was excluded. And in the group HMS5552 dose4, two subjects without follow-up data for HbA1c available were excluded. So the overall number of baseline participants is not consistent with numbers provided in any of the rows in the participant flow module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2hPPG</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Using a standard meal tolerance test, to assess 2-h postprandial glucose (2hPPG). In this test, subjects were received meals standardised by China National Cereals, which supplied by Oils and Foodstuffs Corporation and contained 353 kcal, 75 g carbohydrate, 1.48 g fat, and 8.0 g protein. Collect the blood samples to detect blood glucose 2 hours after starting the meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>HMS5552 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75mgQD oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mgQD oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mgBID oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75mgBID oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, BID/QD oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMS5552</intervention_name>
    <description>75mgQD</description>
    <arm_group_label>HMS5552 dose 1</arm_group_label>
    <other_name>GKA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMS5552</intervention_name>
    <description>100mgQD</description>
    <arm_group_label>HMS5552 dose 2</arm_group_label>
    <other_name>GKA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMS5552</intervention_name>
    <description>50mgBID</description>
    <arm_group_label>HMS5552 dose 3</arm_group_label>
    <other_name>GKA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMS5552</intervention_name>
    <description>75mgBID</description>
    <arm_group_label>HMS5552 dose 4</arm_group_label>
    <other_name>GKA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>QD/BID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male &amp; female, 40~75 years old

          2. T2DM patients，anti-hyperglycemic drug-naïve and on diet &amp; exercise for at least 3
             months, or with glucose controlled by Metformin or α-glucosidase inhibitor alone

          3. HbA1c 7.5~10.5% at screening and pre-randomization

          4. Fasting plasma glucose (FPG)7.0~11.1 millimole/liter (mmol/L, local lab) at screening,
             and 7.0~13.3 millimole/liter (mmol/L, central lab) at pre-randomization

          5. BMI: 19~30kg/m^2 &amp; TG&lt;5.5mmol/L

        Exclusion Criteria:

          1. T1D，secondary DM, pre-DM

          2. kidney diseases or eGFR MDRD&lt;60ml/min/1.73m^2

          3. unstable CVDs

          4. liver diseases

          5. mental or CNS diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalong Zhu, MD，PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 23, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2015</study_first_posted>
  <results_first_submitted>February 5, 2018</results_first_submitted>
  <results_first_submitted_qc>February 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2020</results_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GKA,T2DM,HMS5552</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HMS5552 Dose 1</title>
          <description>HMS5552: 75mgQD</description>
        </group>
        <group group_id="P2">
          <title>HMS5552 Dose 2</title>
          <description>HMS5552: 100mgQD</description>
        </group>
        <group group_id="P3">
          <title>HMS5552 Dose 3</title>
          <description>HMS5552: 50mgBID</description>
        </group>
        <group group_id="P4">
          <title>HMS5552 Dose 4</title>
          <description>HMS5552: 75mgBID</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo, BID/QD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="46"/>
                <participants group_id="P5" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>In the group HMS5552 dose3, a subject without follow-up data for HbA1c available was excluded. And in the group HMS5552 dose4, two subjects without follow-up data for HbA1c available were excluded. So the overall number of baseline participants is not consistent with numbers provided in any of the rows in the participant flow module.</population>
      <group_list>
        <group group_id="B1">
          <title>HMS5552 Dose 1</title>
          <description>HMS5552: 75mgQD</description>
        </group>
        <group group_id="B2">
          <title>HMS5552 Dose 2</title>
          <description>HMS5552: 100mgQD</description>
        </group>
        <group group_id="B3">
          <title>HMS5552 Dose 3</title>
          <description>HMS5552: 50mgBID</description>
        </group>
        <group group_id="B4">
          <title>HMS5552 Dose 4</title>
          <description>HMS5552: 75mgBID</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo: BID/QD</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="49"/>
            <count group_id="B5" value="53"/>
            <count group_id="B6" value="255"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.58" spread="9.159"/>
                    <measurement group_id="B2" value="56.7" spread="7.670"/>
                    <measurement group_id="B3" value="54.92" spread="8.137"/>
                    <measurement group_id="B4" value="55.42" spread="7.659"/>
                    <measurement group_id="B5" value="54.73" spread="8.499"/>
                    <measurement group_id="B6" value="55.88" spread="8.271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="255"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="255"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>percentage of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.44" spread="0.803"/>
                    <measurement group_id="B2" value="8.27" spread="0.639"/>
                    <measurement group_id="B3" value="8.33" spread="0.653"/>
                    <measurement group_id="B4" value="8.46" spread="0.670"/>
                    <measurement group_id="B5" value="8.39" spread="0.780"/>
                    <measurement group_id="B6" value="8.38" spread="0.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FPG</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.933" spread="2.3356"/>
                    <measurement group_id="B2" value="9.127" spread="1.4868"/>
                    <measurement group_id="B3" value="9.390" spread="1.5317"/>
                    <measurement group_id="B4" value="9.859" spread="1.9902"/>
                    <measurement group_id="B5" value="9.277" spread="1.7608"/>
                    <measurement group_id="B6" value="9.518" spread="1.8663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2h PPG</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.042" spread="3.3004"/>
                    <measurement group_id="B2" value="17.429" spread="3.2023"/>
                    <measurement group_id="B3" value="17.243" spread="3.0943"/>
                    <measurement group_id="B4" value="17.884" spread="3.1303"/>
                    <measurement group_id="B5" value="16.950" spread="3.7282"/>
                    <measurement group_id="B6" value="17.509" spread="3.3052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI) units: kg/m^2</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.718" spread="2.8672"/>
                    <measurement group_id="B2" value="25.010" spread="2.9374"/>
                    <measurement group_id="B3" value="24.686" spread="2.3112"/>
                    <measurement group_id="B4" value="25.321" spread="2.5419"/>
                    <measurement group_id="B5" value="25.188" spread="2.6113"/>
                    <measurement group_id="B6" value="25.321" spread="2.5419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis time</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.37" spread="4.053"/>
                    <measurement group_id="B2" value="3.24" spread="4.304"/>
                    <measurement group_id="B3" value="3.27" spread="4.220"/>
                    <measurement group_id="B4" value="2.82" spread="3.230"/>
                    <measurement group_id="B5" value="3.41" spread="4.195"/>
                    <measurement group_id="B6" value="3.23" spread="3.984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>After 12-week Treatment, the Change From Baseline in HbA1c</title>
        <description>Assess the percentage of Hemoglobin A1c (HbA1c) changes at week 12. In the group HMS5552 dose3, a subject without follow-up data for HbA1c available was excluded. And in the group HMS5552 dose4, two subjects without follow-up data for HbA1c available were excluded. So the overall number of baseline participants is not consistent with numbers provided in any of the rows in the participant flow module.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HMS5552 Dose 1</title>
            <description>HMS5552: 75mgQD</description>
          </group>
          <group group_id="O2">
            <title>HMS5552 Dose 2</title>
            <description>HMS5552:100mgQD</description>
          </group>
          <group group_id="O3">
            <title>HMS5552 Dose 3</title>
            <description>HMS5552: 50mgBID</description>
          </group>
          <group group_id="O4">
            <title>HMS5552 Dose 4</title>
            <description>HMS5552: 75mgBID</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo:BID/QD</description>
          </group>
        </group_list>
        <measure>
          <title>After 12-week Treatment, the Change From Baseline in HbA1c</title>
          <description>Assess the percentage of Hemoglobin A1c (HbA1c) changes at week 12. In the group HMS5552 dose3, a subject without follow-up data for HbA1c available was excluded. And in the group HMS5552 dose4, two subjects without follow-up data for HbA1c available were excluded. So the overall number of baseline participants is not consistent with numbers provided in any of the rows in the participant flow module.</description>
          <units>Percentage of glycated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" lower_limit="-0.64" upper_limit="-0.16"/>
                    <measurement group_id="O2" value="-0.65" lower_limit="-0.92" upper_limit="-0.38"/>
                    <measurement group_id="O3" value="-0.79" lower_limit="-1.06" upper_limit="-0.52"/>
                    <measurement group_id="O4" value="-1.12" lower_limit="-1.39" upper_limit="-0.86"/>
                    <measurement group_id="O5" value="-0.35" lower_limit="-0.60" upper_limit="-0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2hPPG</title>
        <description>Using a standard meal tolerance test, to assess 2-h postprandial glucose (2hPPG). In this test, subjects were received meals standardised by China National Cereals, which supplied by Oils and Foodstuffs Corporation and contained 353 kcal, 75 g carbohydrate, 1.48 g fat, and 8.0 g protein. Collect the blood samples to detect blood glucose 2 hours after starting the meal.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HMS5552 Dose 1</title>
            <description>HMS5552: 75mgQD</description>
          </group>
          <group group_id="O2">
            <title>HMS5552 Dose 2</title>
            <description>HMS5552:100mgQD</description>
          </group>
          <group group_id="O3">
            <title>HMS5552 Dose 3</title>
            <description>HMS5552: 50mgBID</description>
          </group>
          <group group_id="O4">
            <title>HMS5552 Dose 4</title>
            <description>HMS5552: 75mgBID</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo:BID/QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2hPPG</title>
          <description>Using a standard meal tolerance test, to assess 2-h postprandial glucose (2hPPG). In this test, subjects were received meals standardised by China National Cereals, which supplied by Oils and Foodstuffs Corporation and contained 353 kcal, 75 g carbohydrate, 1.48 g fat, and 8.0 g protein. Collect the blood samples to detect blood glucose 2 hours after starting the meal.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.669" spread="2.325"/>
                    <measurement group_id="O2" value="-4.945" spread="3.387"/>
                    <measurement group_id="O3" value="-3.898" spread="3.535"/>
                    <measurement group_id="O4" value="-4.899" spread="3.921"/>
                    <measurement group_id="O5" value="-1.987" spread="3.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG</title>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HMS5552 Dose 1</title>
            <description>HMS5552: 75mgQD</description>
          </group>
          <group group_id="O2">
            <title>HMS5552 Dose 2</title>
            <description>HMS5552:100mgQD</description>
          </group>
          <group group_id="O3">
            <title>HMS5552 Dose 3</title>
            <description>HMS5552: 50mgBID</description>
          </group>
          <group group_id="O4">
            <title>HMS5552 Dose 4</title>
            <description>HMS5552: 75mgBID</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo:BID/QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.307" spread="2.000"/>
                    <measurement group_id="O2" value="-0.382" spread="1.602"/>
                    <measurement group_id="O3" value="-0.758" spread="2.150"/>
                    <measurement group_id="O4" value="-1.319" spread="2.258"/>
                    <measurement group_id="O5" value="-0.801" spread="1.752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline in MMTT (Mixed Meal Tolerance Test) β-cell Function Index</title>
        <description>Disposition index, i.e DI, by the insulin secretion sensitivity index-2 (ISSI-2). This is an calculated value which represents the ability of a person's pancreatic beta cells to lower blood glucose. A higher number means the pancreas is better able to secrete insulin and improve glucose levels. HOMA IR is an index used to evaluate the individual's insulin resistance level. The HOMA-IR index of normal individuals is 1. With the increase of insulin resistance, HOMA-IR index will be higher than 1.</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>Both of disposition index and HOMA-IR could reflect the function of β cell.</population>
        <group_list>
          <group group_id="O1">
            <title>HMS5552 Dose 1</title>
            <description>HMS5552: 75mgQD</description>
          </group>
          <group group_id="O2">
            <title>HMS5552 Dose 2</title>
            <description>HMS5552: 100mgQD</description>
          </group>
          <group group_id="O3">
            <title>HMS5552 Dose 3</title>
            <description>HMS5552: 50mgBID</description>
          </group>
          <group group_id="O4">
            <title>HMS5552 Dose 4</title>
            <description>HMS5552: 75mgBID</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo, BID/QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MMTT (Mixed Meal Tolerance Test) β-cell Function Index</title>
          <description>Disposition index, i.e DI, by the insulin secretion sensitivity index-2 (ISSI-2). This is an calculated value which represents the ability of a person's pancreatic beta cells to lower blood glucose. A higher number means the pancreas is better able to secrete insulin and improve glucose levels. HOMA IR is an index used to evaluate the individual's insulin resistance level. The HOMA-IR index of normal individuals is 1. With the increase of insulin resistance, HOMA-IR index will be higher than 1.</description>
          <population>Both of disposition index and HOMA-IR could reflect the function of β cell.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disposition Index</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.292" lower_limit="0.065" upper_limit="0.838"/>
                    <measurement group_id="O2" value="0.198" lower_limit="-0.075" upper_limit="0.532"/>
                    <measurement group_id="O3" value="0.216" lower_limit="0.008" upper_limit="0.532"/>
                    <measurement group_id="O4" value="0.140" lower_limit="-0.010" upper_limit="0.580"/>
                    <measurement group_id="O5" value="0.080" lower_limit="-0.061" upper_limit="0.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOMA-IR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.530" lower_limit="-1.770" upper_limit="0.260"/>
                    <measurement group_id="O2" value="-0.520" lower_limit="-2.050" upper_limit="0.150"/>
                    <measurement group_id="O3" value="-0.550" lower_limit="-1.930" upper_limit="0.260"/>
                    <measurement group_id="O4" value="-1.185" lower_limit="-2.485" upper_limit="-0.385"/>
                    <measurement group_id="O5" value="-0.680" lower_limit="-1.650" upper_limit="0.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From randomization to 7 days after 12-week treatment</time_frame>
      <desc>Note: Hypoglycemia in this study was collected and analyzed as Special attention event separated from the analysis of Any other Advance Event. The Number Affected by Hypoglycemia was not included in the Total Number Affected by Any Other (Not including Serious) Adverse Event Above the Frequency Threshold in the third table.</desc>
      <group_list>
        <group group_id="E1">
          <title>HMS5552 Dose 1</title>
          <description>HMS5552: 75mgQD</description>
        </group>
        <group group_id="E2">
          <title>HMS5552 Dose 2</title>
          <description>HMS5552: 100mgQD</description>
        </group>
        <group group_id="E3">
          <title>HMS5552 Dose 3</title>
          <description>HMS5552: 50mgBID</description>
        </group>
        <group group_id="E4">
          <title>HMS5552 Dose 4</title>
          <description>HMS5552: 75mgBID</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo: BID/QD</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Right Achilles Tendon Rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lacunar Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Right Cerebral Infarction Of Basal Ganglia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Function Abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Protein Urine Present</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>White Blood Cells Urine Positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>High Density Lipoprotein Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="10" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yi Zhang</name_or_title>
      <organization>Hua Medicine</organization>
      <phone>+86-21-58869997 ext 3269</phone>
      <email>yzhang@huamedicine.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

